Identification of CD159A as a prognostic and immune biomarker in kidney renal clear cell carcinoma.

Jing Zhang, Xin Li, Xiaoqian Yu, Wenying Jiang, Xiaoyun He, Cheng Mei, Chunlin Ou

Abstract read

In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jing ZhangDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Xin LiDepartment of Immunology, Xiangya School of Basic Medicine, Central South University, Changsha, 410000, Hunan, China.

Xiaoqian YuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Wenying JiangDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Xiaoyun HeDepartments of Ultrasound Imaging, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Cheng MeiDepartment of Blood Transfusion, Clinical Transfusion Research Center, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. meicheng@csu.edu.cn.

Chunlin OuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China. ouchunlin@csu.edu.cn.

Funding

Central South University Innovation-Driven Research Programme 2023CXQD075Natural Science Foundation of Hunan Province 2023JJ40975

6 · The paper itself

Abstract

Kidney renal clear cell carcinoma (KIRC) is a highly aggressive malignant tumor, and its occurrence and progression are influenced by tumor microenvironment (TME). CD159A, a natural killer (NK) cell inhibitory receptor, has emerged as a critical immune checkpoint in TME. We conducted a comprehensive multi-omics analysis of CD159A expression, prognostic significance, and functional enrichment in KIRC. Additionally, quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC) were employed to perform CD159A expression in the Xiangya KIRC validation cohort. Furthermore, in vitro experiments were evaluated through cell proliferation, colony formation, and flow cytometry (FC) analysis of apoptosis in KIRC cell lines. Our study found that CD159A expression was significantly upregulated in KIRC tissues compared to normal tissues, as confirmed by TCGA data and the Xiangya KIRC validation cohort. In machine learning analyses, the biological significance of the regulatory network risk factors of the CD159A-HLA-E pathway is immunosuppressive receptors or abnormal antigen presentation that may promote immune escape. Elevated CD159A levels were observed in NK cells and CD8

Indexed as

Biomarkers, TumorCarcinoma, Renal CellKidney NeoplasmsReceptors, ImmunologicCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansKiller Cells, NaturalMalePrognosisTumor MicroenvironmentBiomarkers, TumorReceptors, ImmunologicBiomarkerCD159AImmune checkpointImmunotherapySingle-cell RNA sequencing

Identifiers

PMID40935873

DOI10.1038/s41598-025-18515-8

PMCPMC12426227

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.